Floatz logo

EFTRENONACOG ALFA

Hemophilia B

Hospices Civils de Lyonprotein_peptidePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
81/ 100

Competitive context

32 Active assets in the Hemophilia B cohort.

Asset / SponsorPhaseRating
Factor Ix
CSL Behring
Phase 4A
Eptacog Alfa
AryoGen Pharmed Co.
Phase 4A
Benefix
Pfizer
Phase 4A
Nonacog Beta Pegol
Novo Nordisk A/S
Phase 3A
Factor Ix
CSL Behring
Phase 4BBB

View all 50 →

Same molecule, other indications

EFTRENONACOG ALFA is also rated in:

severe hemophilia BDormant
BB
Indicative ·
66 / 100
View asset →
inherited blood coagulation disorderDormant
CC
Indicative ·
47 / 100
View asset →
hemophilia BDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →